Agilent Technologies has announced a strategic collaboration with Veeda Lifesciences to strengthen regulatory-aligned analytical and bioanalytical workflows supporting biopharma development. 

As part of the collaboration, the two companies will establish a joint Center of Excellence (CoE) at Veeda’s biopharma facility in Bengaluru.  

The CoE will function as a scalable analytics and regulatory-readiness hub focused on developing and validating end-to-end analytical workflows for next-generation therapies, including GLP-1-based drugs, where sensitivity, throughput, and data integrity are critical. 

“As GLP-1 and other complex therapies move rapidly through development, the need for robust, regulatory-aligned analytics becomes increasingly critical,” said Nandakumar Kalathil, Country General Manager, Agilent India. “Through our collaboration with Veeda, we aim to support biopharma organizations with workflow-driven analytical approaches that strengthen data quality, compliance, and confidence across the development lifecycle.” 

Bharat Bhardwaj, Vice President and General Manager, Asia Pacific, Agilent Technologies, said, “As Biopharma innovation accelerates across the region, the need for integrated, regulatory ready analytical ecosystems is becoming increasingly critical. This collaboration between Agilent and Veeda Lifesciences reflects our commitment to enabling customers with advanced, scalable solutions that support confident decision-making across the drug development lifecycle, while Asia Pacific’s role as a hub for high quality globally relevant biopharma research.” 

“Biopharma companies today require analytical capabilities that are inspection-ready from the outset,” said Binoy Gardi, Group CEO and Managing Director, Veeda Lifesciences. “By collaborating with Agilent, we are strengthening our ability to deliver integrated, regulatory-aligned analytical workflows that support faster decision-making and smoother progression from early development through clinical and manufacturing stages.”

Sanjib Banerjee, Chief Operating Officer (COO), Biopharma at Veeda Lifesciences, added, “This expansion of our service portfolio establishes an advanced, technology-driven platform for the structural analytical characterization of complex biologics—including peptides (GLP-1), monoclonal antibodies, antibody–drug conjugates (ADCs) and other therapeutic proteins. Built on Veeda’s established capabilities in in depth proteomics, glycoproteomic and process-related impurities analysis, and leveraging Agilent’s high-end Mass Spectrometry, this creates an integrated, regulatory-aligned analytical ecosystem under one roof.”